Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab, tremelimumab, and radiotherapy in recurrent gynecologic cancer
NCT03277482Phase 1Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jun 2018
- Primary completion
- Jul 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of durvalumab and tremelimumab in gynecologic cancer, Malignant ovarian neoplasm (OC), vaginal cancer and 2 more, sponsored by Dana-Farber Cancer Institute. Started Jun 2018; status: terminated.
02
Drugs
durvalumabtremelimumab
03
Conditions
gynecologic cancerMalignant ovarian neoplasm (OC)vaginal cancervulvar cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT03277482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03277482.